The US Food and Drug Administration (FDA) approved the first-ever anti-depression nasal spray, Spravato. The pharmaceutical ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

A nasal spray that contains esketamine — a potent derivative of ketamine — can now be taken on its own to treat adults with ...

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as mental health medicine. A recent approval made by the FDA could be a great step ...

Here's what doctors want you to know about Spravato, plus potential side effects to be aware of. Thea Gallagher, PsyD, is a clinical associate professor at NYU Langone Health and cohost of the ...

Spravato is now the first stand-alone therapy for treatment-resistant depression, for patients who haven't responded to oral ...

These side effects and the potential risk of harmful dependence have led to the FDA mandating a special treatment strategy for providing Spravato to patients, known as a Risk Evaluation and ...

Gregory Mattingly, MD, president, Midwest Research Group, founding partner, St. Charles Psychiatric Associates, discusses the ...

Spravato targets glutamate in the brain, which is the most abundant excitatory neurotransmitter. Since there are some side effects, including sedation, respiratory depression and misuse ...

The Food and Drug Administration recently expanded approval for Spravato, an antidepressant nasal spray used to treat ...